Sarfaraz K. Niazi
Biosimilarity
The FDA Perspective
Ebook (EPUB Format)
Summary:The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity.a An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.Features: First comprehensive analysis based on new guidelines and approval packages of several biosimilarsPresents the first approach to challenge FD…
Mehr
Beschreibung
Summary:The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity.a An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.Features: First comprehensive analysis based on new guidelines and approval packages of several biosimilarsPresents the first approach to challenge FDA in reducing or eliminating any testing in patients.Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelinesProvides model CQA and Analytical Similarity testing protocolsa for cytokines and monoclonal antibodiesAllow creation of a fast-to-market pathway to develop biosimilars
CHF 57.40
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
V210:
Noch nicht erschienen, Januar 2021
Produktdetails
- ISBN: 978-1-315-35137-7
- EAN: 9781315351377
- Produktnummer: 29181326
- Verlag: Taylor & Francis Ltd.
- Sprache: Englisch
- Erscheinungsjahr: 2018
- Seitenangabe: 436 S.
- Plattform: EPUB
- Abbildungen: 2 line equations and 2 total equations, 79 farbige Abbildungen
Über den Autor
Sarfaraz K. Niazi Ph.D, is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.
59 weitere Werke von Sarfaraz K. Niazi:
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (EPUB Format)
CHF 66.35
The FDA Perspective
Ebook (PDF Format)
CHF 66.35
The FDA Perspective
Ebook (PDF Format)
CHF 414.10
The FDA Perspective
Ebook (PDF Format)
CHF 435.40
The FDA Perspective
Ebook (PDF Format)
CHF 435.40
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (EPUB Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 66.35
The FDA Perspective
Ebook (EPUB Format)
CHF 1,175.20
The FDA Perspective
Ebook (PDF Format)
CHF 435.40
The FDA Perspective
Ebook (PDF Format)
CHF 1,175.20
The FDA Perspective
Ebook (PDF Format)
CHF 435.40
The FDA Perspective
Ebook (PDF Format)
CHF 435.40
The FDA Perspective
Ebook (EPUB Format)
CHF 81.25
The FDA Perspective
Ebook (EPUB Format)
CHF 66.35
The FDA Perspective
Ebook (EPUB Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (EPUB Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 81.25
The FDA Perspective
Ebook (PDF Format)
CHF 116.10
Bewertungen
0 von 0 Bewertungen
Anmelden
Keine Bewertungen gefunden. Seien Sie der Erste und teilen Sie Ihre Erkenntnisse mit anderen.